Gastrointestinal (GI) disorders include functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn's disease (CD) and colitis. Some gastrointestinal drug can control or moderate the symptoms of gastrointestinal disorders.

The global Gastrointestinal Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Gastrointestinal Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Gastrointestinal Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Gastrointestinal Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Gastrointestinal Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
AstraZeneca
Sanofi
Bayer
Pfizer
GlaxoSmithKline
Teva
Zeria（Tillotts）
Perrigo
Boehringer Ingelheim
Purdue Pharma
C.B. Fleet
Abbott
Jiangzhong
Xian-Janssen

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Prescription Gastrointestinal Drug
OTC Gastrointestinal Drug

Segment by Application
Chronic Gastritis
Functional Dyspepsia
Peptic Ulcer
Acute Gastroenteritis
Other